Equities research analysts expect Insulet Corporation (NASDAQ:PODD) to report ($0.07) earnings per share for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Insulet Corporation’s earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.15). Insulet Corporation reported earnings per share of ($0.16) during the same quarter last year, which suggests a positive year over year growth rate of 56.3%. The company is expected to announce its next quarterly earnings results on Monday, February 26th.
On average, analysts expect that Insulet Corporation will report full year earnings of ($0.42) per share for the current financial year, with EPS estimates ranging from ($0.53) to ($0.35). For the next financial year, analysts forecast that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.62) to $0.30. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Insulet Corporation.
Insulet Corporation (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.06. Insulet Corporation had a negative return on equity of 43.85% and a negative net margin of 6.66%. The company had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. During the same quarter in the prior year, the company posted ($0.05) EPS. The firm’s revenue was up 28.4% on a year-over-year basis.
In other Insulet Corporation news, Director James C. Mullen purchased 2,500 shares of Insulet Corporation stock in a transaction on Monday, November 13th. The stock was bought at an average cost of $67.45 per share, with a total value of $168,625.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.60% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Insulet Corporation by 11.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after acquiring an additional 235 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Insulet Corporation in the 2nd quarter valued at about $180,000. Diversified Trust Co purchased a new stake in Insulet Corporation in the 2nd quarter valued at about $205,000. Wrapmanager Inc. purchased a new stake in Insulet Corporation in the 2nd quarter valued at about $217,000. Finally, RNC Capital Management LLC purchased a new stake in Insulet Corporation during the second quarter worth about $225,000.
COPYRIGHT VIOLATION WARNING: “-$0.07 EPS Expected for Insulet Corporation (PODD) This Quarter” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/11/21/0-07-eps-expected-for-insulet-corporation-podd-this-quarter.html.
Insulet Corporation (PODD) traded up $1.16 during midday trading on Friday, reaching $71.80. The company had a trading volume of 314,300 shares, compared to its average volume of 499,586. Insulet Corporation has a 1-year low of $32.12 and a 1-year high of $72.26. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88.
Insulet Corporation Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.